Cannabis research is dangerously behind the reality of legalization, and the field needs new study designs | Research

The takeaway

With 63% of the US population having access to medicinal cannabis, the scientific literature does not adequately inform policy, medical decisions, or harm reduction, and traditional research barriers require innovative study designs to overcome.

Researchers, policymakers, cannabis users wanting to understand why the evidence base is so limited, and anyone interested in science policy.

63% of US population has cannabis access; science can't keep up due to regulatory barriers

What the researchers found

63% of the US population has access to medicinal cannabis markets offering increasingly diverse and potent products. The scientific literature does not adequately inform public policy, medical decision making, or harm reduction approaches. Key barriers include federal scheduling, DEA licensing, and limited approved research cannabis.

Why it matters

Millions of people are using cannabis products with minimal scientific guidance. The regulatory barriers that prevent proper research create an information vacuum filled by marketing claims and anecdotes, which is harmful to both users and non-users.

The numbers in context

63% of US population with medicinal cannabis access. Increasingly diverse and potent products available. Research barriers include federal Schedule I status, DEA licensing requirements, and NIDA-supplied cannabis that doesn't match commercial products.

How the study worked

Review examining the state of cannabis research for commonly treated conditions, barriers to research progress, and proposed innovative research designs to address knowledge gaps.

What this study cannot tell us

Focuses on US regulatory context, though similar barriers exist in other countries. Proposed innovative designs have not been fully validated. Does not provide a timeline for when the knowledge gap might close.

How to read the evidence

Moderate: well-argued review from active researchers identifying specific barriers and proposing solutions.

When this study was published

Published in 2019.

The bigger picture

The cannabis knowledge gap is not just a scientific problem but a public health emergency. People are making health decisions daily about a product whose effects are largely unstudied using modern methods. The field needs the same urgency applied to other public health crises.

Questions still open

Could observational studies of real-world cannabis users provide useful data while RCT barriers persist? Would federal rescheduling be sufficient to accelerate research, or are other structural changes needed? Can the research community catch up before the commercial market makes it irrelevant?

Common questions

Why don't we know more about cannabis?

Federal Schedule I classification creates massive research barriers: DEA licensing, restricted funding, and only government-supplied cannabis that doesn't match what consumers actually use. This has created a gap between rapidly expanding markets and limited evidence.

How can cannabis research catch up?

The authors propose innovative designs including observational studies of existing users, pragmatic trials, and leveraging the diversity of state markets as natural experiments, rather than waiting for federal rescheduling.

Read the original research

Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(11), 1289-1294

View on PubMed ↗Publisher’s paper ↗

Citation

Hutchison, Kent E; Bidwell, L Cinnamon; Ellingson, Jarrod M; Bryan, Angela D. (2019). Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(11), 1289-1294. https://doi.org/10.1016/j.jval.2019.05.005